Companies: Astellas Pharma, Astellas Pharma US, Inc.
Drugs: Vyloy, zolbetuximab, zolbetuximab-clzb
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
200% citation coverage1 peer-reviewed sources
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
Intelligence Snapshot
Executive Summary
Astellas Pharma secured FDA approval for zolbetuximab-clzb (Vyloy) on October 18, 2024, marking the first and only claudin 18.2–targeted therapy approved in the U.S. for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Key Insights
-
Vyloy is indicated for use in combination with fluoropyrimidine- and platinum-containing…
Vyloy is indicated for use in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with HER2-negative disease whose tumors express claudin 18.2.
-
The recommended maintenance dose is 400 mg/m² intravenously once every 2 weeks or 600…
The recommended maintenance dose is 400 mg/m² intravenously once every 2 weeks or 600 mg/m² once every 3 weeks , offering dosing flexibility in clinical practice.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Quick Answer
Astellas Pharma secured FDA approval for zolbetuximab-clzb (Vyloy) on October 18, 2024, marking the first and only claudin 18.2–targeted therapy approved in the U.S. for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Key Questions
- How many gastric cancers are HER2-positive?
- Can you take zolbetuximab every 2 weeks?
- What is the approved indication for Vyloy?
- Is Vyloy the only claudin 18.2–targeted therapy approved in the U.S.?
- What is the approval date for Vyloy?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Vyloy.
Unlock full calendar →Astellas Pharma pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents12 sections
FDA Approves Vyloy for HER2-Negative Gastric and GEJ Cancer
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
IntelligenceRegulatory Impact
FDA and Food and Drug Administration decisions frame this story. Regulatory relevance is high for HER2-negative gastric cancer, with Vyloy and zolbetuximab most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- Astellas Pharma secured FDA approval for zolbetuximab-clzb (Vyloy) on October 18, 2024, marking the first and only claudin 18.2–targeted therapy approved in the U.S. for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
- Vyloy is indicated for use in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with HER2-negative disease whose tumors express claudin 18.2.
- The recommended maintenance dose is 400 mg/m² intravenously once every 2 weeks or 600 mg/m² once every 3 weeks, offering dosing flexibility in clinical practice.
IntelligenceCompetitive Intelligence
Astellas Pharma and Astellas Pharma US, Inc. are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
What Changed: The Approval
Astellas Pharma secured a first-line indication for zolbetuximab-clzb (Vyloy) on October 18, 2024. The drug is approved for patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). The approved use is in combination with fluoropyrimidine- and platinum-containing chemotherapy.
Astellas describes Vyloy as the first and only CLDN18.2-targeted therapy approved in the U.S. for this indication. The approval represents the first CLDN18.2-targeted option in the U.S. gastric cancer market, addressing an unmet need in the HER2-negative population.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for HER2-negative gastric cancer. Expect implications for pricing, access, and launch sequencing.
Why It Matters: Patient Population and Disease Context
Approximately one in five gastric cancers are HER2-positive, which means the HER2-negative population represents a substantial treatment opportunity. The approval targets claudin 18.2–positive tumors within that HER2-negative cohort. Patients with advanced gastric and GEJ adenocarcinoma now have access to a targeted therapy designed to address CLDN18.2 expression, a biomarker present in a significant portion of gastric tumors.
IntelligenceStrategic Takeaways
Astellas Pharma secured FDA approval for zolbetuximab-clzb (Vyloy) on October 18, 2024, marking the first and only claudin 18.2–targeted therapy approved in the U.S. for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. Vyloy is indicated for use in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with HER2-negative disease whose tumors express claudin 18.2. The r
Dosing and Administration
Vyloy's recommended maintenance dosage consists of 400 mg/m² intravenously once every 2 weeks or 600 mg/m² once every 3 weeks, following an initial loading dose. This dosing schedule offers clinical flexibility and may support different treatment contexts or patient tolerability profiles. The every-2-weeks option provides an alternative for patients who may benefit from more frequent dosing intervals.
IntelligenceEvidence Quality
Grounded in 1 peer-reviewed source.
What to Watch: Pipeline and Future Catalysts
Astellas is advancing zolbetuximab in additional settings. A Phase 3 trial (NCT06901531) is recruiting patients to evaluate zolbetuximab in combination with pembrolizumab and chemotherapy in gastric cancer. A safety study (NCT06902545) is also recruiting in South Korea to observe Vyloy tolerability in gastric and GEJ cancer patients. These ongoing trials represent the next wave of data generation for the zolbetuximab program and may yield additional clinical insights in combination settings and regional populations.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | RECRUITING | PHASE3 | Astellas Pharma Global Development, Inc. |
| NCT06902545 | A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. | RECRUITING | — | Astellas Pharma Korea, Inc. |
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | RECRUITING | PHASE3 | Astellas Pharma Global Development, Inc. |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | Astellas Pharma Global Development, Inc. |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | RECRUITING | PHASE3 | AstraZeneca |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| AstraZeneca | HER2-negative gastric cancer | 2 |
| Astellas Pharma Global Development, Inc. | HER2-negative gastric cancer | 1 |
| BeiGene | HER2-negative gastric cancer | 1 |
| Samsung Medical Center | HER2-negative gastric cancer | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | HER2-negative gastric cancer | 1 |
| Alliance for Clinical Trials in Oncology | HER2-negative gastric cancer | 1 |
Timeline
- Recruiting trial NCT06901531 (PHASE3)
- Recruiting trial NCT06902545 (phase n/a)
- Recruiting trial NCT06901531 (PHASE3)
- Active_Not_Recruiting trial NCT03816163 (PHASE2)
- Recruiting trial NCT07431281 (PHASE3)
Frequently Asked Questions
How many gastric cancers are HER2-positive?
Approximately one in five gastric cancers are considered HER2-positive. This means the HER2-negative population, which is eligible for Vyloy, comprises roughly four-fifths of gastric cancer cases.
Can you take zolbetuximab every 2 weeks?
Yes. The recommended maintenance dosage for zolbetuximab is 400 mg/m² intravenously once every 2 weeks, or alternatively 600 mg/m² once every 3 weeks. Dosing frequency can be selected based on clinical judgment and patient factors.
What is the approved indication for Vyloy?
Vyloy is approved for use in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express claudin 18.2.
Is Vyloy the only claudin 18.2–targeted therapy approved in the U.S.?
Astellas states that Vyloy is the first and only claudin 18.2–targeted therapy approved in the U.S. for advanced gastric and gastroesophageal junction cancer.
What is the approval date for Vyloy?
The FDA approved zolbetuximab-clzb (Vyloy) on October 18, 2024.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About HER2-negative gastric cancer
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow Vyloy developments
FDA her2-negative gastric cancer alerts and Vyloy pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 100/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
